Head to Head Analysis: PACS Group (NYSE:PACS) and BioNexus Gene Lab (NASDAQ:BGLC)

PACS Group (NYSE:PACS) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Profitability

This table compares PACS Group and BioNexus Gene Lab’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PACS Group	N/A	N/A	N/A
BioNexus Gene Lab	-30.70%	-35.54%	-29.08%

Risk and Volatility

PACS Group has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, BioNexus Gene Lab has a beta of 5.2, suggesting that its share price is 420% more volatile than the S&P 500.

Insider & Institutional Ownership

18.9% of BioNexus Gene Lab shares are held by institutional investors. 0.7% of BioNexus Gene Lab shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares PACS Group and BioNexus Gene Lab”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PACS Group	$3.11 billion	0.61	$112.87 million	N/A	N/A
BioNexus Gene Lab	$9.51 million	1.01	-$1.60 million	N/A	N/A

PACS Group has higher revenue and earnings than BioNexus Gene Lab.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for PACS Group and BioNexus Gene Lab, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PACS Group	1	1	3	0	2.40
BioNexus Gene Lab	1	0	0	0	1.00

PACS Group presently has a consensus price target of $26.25, suggesting a potential upside of 112.38%. Given PACS Group’s stronger consensus rating and higher probable upside, research analysts plainly believe PACS Group is more favorable than BioNexus Gene Lab.

Summary

PACS Group beats BioNexus Gene Lab on 8 of the 12 factors compared between the two stocks.

About PACS Group

PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.